首页|The Pennsylvania Postmarket Multlcenter Experience With Flow Redirection Endoluminal Device
The Pennsylvania Postmarket Multlcenter Experience With Flow Redirection Endoluminal Device
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
BACKGROUND: The flow redirection endoluminal device (FRED) is a novel self-expanding double-layer nitinol braided flow diverter that recently received FDA approval。 However， early postmarket studies from the United States are lacking。 OBJECTIVE: To report our short-term multicenter experience。 METHODS; Series of consecutive patients undergoing FRED treatment for intracranial an-eurysms were queried from prospectively maintained registries at 4 North-American Centers in Pennsylvania (February 2020-June 2021)。 The pertinent baseline demographics， aneurysmal characteristics， and procedural outcomes were collected and analyzed， with primary outcome of aneurysmal occlusion and secondary outcome of safety and complications。
FREDAneurysmFlow diversion
Mohamed M. Salem、Svetlana Kvint、Philipp Hendrix、Fadi Al Saiegh、Avi A. Gajjar、Omar Choudhri、Brian T. Jankowitz、Oded Goren、Bradley A. Gross、Pascal Jabbour、Michael Lang、Clemens M. Schirmer、Stavropoula I.Tjoumakaris、Christoph J. Griessenauer、Jan-Karl Burkhardt
展开 >
Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia
NSTL
